US Edition‘Remarkable’ Pancreatic Cancer Jab Offers Longer Survival Hope for Patients
UNITED KINGDOM, AUG 11 – The vaccine ELI-002 2P triggered strong immune responses in 68% of patients and extended survival beyond standard rates in pancreatic and bowel cancer trials.
- A Phase 1 trial published on Monday tested the ELI-002 2P vaccine on 25 patients with pancreatic and bowel cancer in the US.
- The vaccine targets KRAS mutations, common in 90% of pancreatic cancers, aiming to prevent recurrence by boosting immune responses after surgery.
- In the trial, 68% of participants mounted strong immune reactions, and those with the most robust responses experienced extended survival and longer periods without cancer recurrence, lasting over 15 months.
- Patients with pancreatic cancer lived for nearly two and a half years after vaccination, notably longer than the usual one-year survival rate of 30%, prompting researchers to describe the results as remarkable.
- While the vaccine shows promise and can be made off-the-shelf, experts urge larger trials to confirm benefits and understand varied patient responses before clinical use.
17 Articles
17 Articles
A phase 1 clinical trial of a type of immunotherapy against pancreatic and colorectal cancer can help prolong long-term, non-recurrence-free existence in some patients, according to the results published by Nature Medicine. This experimental therapeutic vaccine, called ELI-002 2P, which unlike other immunotherapies is not personalized but general, is designed to help the immune system recognize and attack cancer cells with a KRAS mutation, which…
Fresh hope for pancreatic cancer patients as new vaccine shows promise in early trial
The new vaccine, which has shown promise in an early trial involving 20 pancreatic cancer patients and five with bowel cancer, has been developed to help the body's immune system find and attack cancer cells.
Evening Standard
‘Remarkable’ pancreatic cancer jab offers longer survival hope for patients
Pancreatic cancer has very poor survival odds.
A universal vaccine against pancreatic cancer has shown promising results in an initial clinical trial, its developers say it does not prevent the appearance of cancer, but it may reduce the likelihood of it appearing again. Related Video: Women Have to Face Cancer with Low Resources and Lack of Medicines in Jalisco Video. How Can You Prevent Cancer? Pancreatic cancer is a particular concern. The five-year survival rate is about 13%, and up to 8…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
